Triple Negative Breast Neoplasms: all 1,163 studies

Page 11 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast CancerCompletedNCT03243331Phase 1
• Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast CancerTerminatedNCT03225547Phase 2
• A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedNCT03219268Phase 1
• A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast CancerTerminatedNCT03186937Phase 2
• QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerActive, not recruitingNCT03168880Phase 3
• Comparison of the Breast Tumor MicroenvironmentCompletedNCT03165487
• Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast CancerCompletedNCT03164993Phase 2
• DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCompletedNCT03154749Phase 2
• Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast CancerStatus unknownNCT03151447Phase 1
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer PatientsStatus unknownNCT03145961Phase 2
• Expanded Access to VeliparibNo longer availableNCT03123211
• Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)CompletedNCT03109080Phase 1
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
• Ribociclib and Bicalutamide in AR+ TNBCActive, not recruitingNCT03090165Phase 1/2
• Tracking Triple-negative Breast Cancer Evolution Through TherapyActive, not recruitingNCT03077776Not applicable
• A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
• A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
• Individual Patient Expanded Access-Glembatumumab VedotinNo longer availableNCT03067935
• Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast CancerTerminatedNCT03055312Phase 3
• Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
• A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast CancerSuspendedNCT03002103Phase 3
• Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCompletedNCT02996825Phase 1
• Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast CancerTerminatedNCT02993094Phase 1/2
• Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)SuspendedNCT02993068Not applicable
• Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast CancerNo longer availableNCT02985658
• Neoadjuvant Carboplatin in Triple Negative Breast CancerCompletedNCT02978495Phase 2
• Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast CancerCompletedNCT02977468Phase 1
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedNCT02936102Phase 1
• Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerWithdrawnNCT02929576Phase 3
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabCompletedNCT02926196Phase 3
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerSuspendedNCT02897050Phase 2
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerActive, not recruitingNCT02876107Phase 2
• Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingNCT02826434Phase 1
• Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy AloneTerminatedNCT02806258Phase 1/2
• T-Cell Therapy for Advanced Breast CancerActive, not recruitingNCT02792114Phase 1
• Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyCompletedNCT02789332Phase 2
• A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT02755272Phase 2
• Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerActive, not recruitingNCT02750358Phase 2
• DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast CancerActive, not recruitingNCT02744053Early Phase 1
• Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer PatientsStatus unknownNCT02694224Phase 2
• Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast CancerStatus unknownNCT02685657Phase 2
• A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast CancerWithdrawnNCT02685306Phase 2
• Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerCompletedNCT02685059Phase 2
• Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer PatientsStatus unknownNCT02681562Phase 2
• Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast CancerStatus unknownNCT02670668Not applicable
• Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer PatientsStatus unknownNCT02670109Phase 2
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
• TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA SignatureActive, not recruitingNCT02641847Phase 2/3
• A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.Status unknownNCT02639832
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
• A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerWithdrawnNCT02637375Not applicable
• A Study of LY2880070 in Participants With Advanced or Metastatic CancerCompletedNCT02632448Phase 1/2
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
• Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast CancerStatus unknownNCT02595138Phase 3
• Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast CancerCompletedNCT02593227Phase 2
• A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersStatus unknownNCT02583542Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-mesoStatus unknownNCT02580747Phase 1
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)CompletedNCT02580448Phase 1/2
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)TerminatedNCT02576665Phase 1
• ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)CompletedNCT02546934Phase 3
• A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1
• The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast CancerWithdrawnNCT02539017Phase 2
• Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBCCompletedNCT02531425Phase 1
• Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of AfatinibStatus unknownNCT02511847Phase 2
• Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT02499367Phase 2
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerActive, not recruitingNCT02488967Phase 3
• Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTerminatedNCT02474173Phase 1
• Breast-Conserving Therapy in Patients With Triple-Negative Breast CancerStatus unknownNCT02464774Not applicable
• Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of SurgeryActive, not recruitingNCT02455791Not applicable
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
• Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyWithdrawnNCT02427581Phase 1
• Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT02393794Phase 1/2
• PCA062 in pCAD-positive Tumors.CompletedNCT02375958Phase 1
• A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorTerminatedNCT02365662Phase 1
• S-equol in Women With Triple Negative Breast CancerCompletedNCT02352025Early Phase 1
• Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant ChemotherapyCompletedNCT02348320Phase 1
• Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) PatientsTerminatedNCT02348281Phase 2
• Pre-operative Zoledronate in Triple Negative Breast CancerTerminatedNCT02347163Phase 2
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT02341911Phase 2
• Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncerWithdrawnNCT02338531Phase 2
• RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uIDCompletedNCT02316457Phase 1
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsCompletedNCT02307240Phase 1
• Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeActive, not recruitingNCT02276443Not applicable
• Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mmCompletedNCT02266420Not applicable
• Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast CancerCompletedNCT02247037
• Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT02225470Phase 3
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerTerminatedNCT02183805Phase 2
• Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnNCT02161679Phase 2
• Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast CancerCompletedNCT02130700Phase 2
• Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedNCT02071862Phase 1

← Triple Negative Breast Neoplasms overview